Latest Breaking News On - V koneti rao - Page 1 : comparemela.com

Pharming N : Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs) - Form 6-K -December 15, 2023 at 06:20 am EST

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 .

United kingdomNoord hollandUnited statesCity ofGulbu uzelEthan metelenisAnurag relanHeather robertsonV koneti raoMichael levitanPharming groupnvCommission file numberPharming groupInvestor relations corporate communicationsLifespring life sciences communicationNational institutes of health

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Noord hollandCity ofUnited kingdomUnited statesHeather robertsonAnurag relanEthan metelenisMichael levitanV koneti raoGulbu uzelLifespring life sciences communicationNational institutes of healthPharming groupDrug administrationInvestor relations corporate communicationsClinical immunodeficiency program

Pharming Group Announces Development Plans For Leniolisib For Additional Primary Immunodeficiencies (Pids)

Pharming Group Announces Development Plans For Leniolisib For Additional Primary Immunodeficiencies (Pids)
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomNoord hollandUnited statesAnurag relanMichael levitanGulbu uzelV koneti raoHeather robertsonEthan metelenisInvestor relations corporate communicationsLifespring life sciences communicationNational institutes of healthPharming groupnvNational institute of allergyClinical immunodeficiency program

Pharming Group N V : Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated

National institutes of healthUnited statesUnited kingdomCity ofNoord hollandV koneti raoEthan metelenisHeather robertsonMichael levitanVirgil dalmDan caleyAnurag relanVp investor relations corporate communicationsDrug administrationExchange commissionMeeting of the american society hematology

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

/PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces data, including new evidence, from an.

National institutes of healthUnited statesUnited kingdomCity ofNoord hollandV koneti raoEthan metelenisHeather robertsonMichael levitanVirgil dalmDan caleyAnurag relanVp investor relations corporate communicationsDrug administrationExchange commissionMeeting of the american society hematology